A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study
H Reinecke, C Engelbertz, R Bauersachs… - Circulation, 2023 - Am Heart Assoc
Background: Non–vitamin K oral anticoagulants have become the standard therapy for
preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation (AF) …
preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation (AF) …
A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 …
H Reinecke, C Engelbertz, R Bauersachs… - Circulation, 2023 - Am Heart Assoc
BACKGROUND: Non–vitamin K oral anticoagulants have become the standard therapy for
preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation (AF) …
preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation (AF) …
A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 …
H Reinecke, C Engelbertz, R Bauersachs, G Breithardt… - Circulation, 2022 - europepmc.org
Background Non-vitamin K oral anticoagulants have become the standard therapy for
preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation (AF) …
preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation (AF) …
A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 …
H Reinecke, C Engelbertz, R Bauersachs, G Breithardt… - 2023 - pubmed.ncbi.nlm.nih.gov
Background Non-vitamin K oral anticoagulants have become the standard therapy for
preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation (AF) …
preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation (AF) …
[HTML][HTML] A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA …
H Reinecke, C Engelbertz, R Bauersachs… - Circulation, 2023 - ncbi.nlm.nih.gov
Background: Non–vitamin K oral anticoagulants have become the standard therapy for
preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation (AF) …
preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation (AF) …
A Randomized Controlled Trial Comparing Apixaban to the Vitamin K-antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 study.
H Reinecke, C Engelbertz, R Bauersachs, G Breithardt… - Circulation, 2022 - europepmc.org
Background: Non-vitamin K oral anticoagulants (NOACs) have become the standard therapy
for preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation …
for preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation …